Chemours Gestion
Gestion contrôle des critères 2/4
Le PDG Chemours est Denise M. Dignam, nommé en Feb2024, a un mandat de 2.25 ans. La rémunération annuelle totale est $ 8.60M, composée du salaire de 12.3% et des bonus 87.7%, y compris les actions et options de la société. détient directement 0.053% des actions de la société, d'une valeur de $ 1.89M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.3 ans et 2.2 ans.
Informations clés
Denise M. Dignam
Directeur général
US$8.6m
Rémunération totale
| Pourcentage du salaire du PDG | 12.32% |
| Durée du mandat du directeur général | 2.3yrs |
| Propriété du PDG | 0.05% |
| Durée moyenne d'occupation des postes de direction | 2.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 2.2yrs |
Mises à jour récentes de la gestion
Recent updates
Article d'analyse • May 08
The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...Seeking Alpha • May 04
Chemours: Thesis Materialization In 2026 (Rating Downgrade)
Summary Chemours Company has delivered a 120%+ RoR in under six months, driven by strong refrigerant segment growth, especially Opteon adoption. Despite recent outperformance, CC now trades above my fair value target ($30/share), prompting a shift to a 'HOLD/Neutral' rating and portfolio rotation. CC remains fundamentally sound but faces persistent risks: high leverage ($3.5B net debt), regulatory liabilities, and cyclical end-market exposure, especially in TiO2. Future upside hinges on continued refrigerant growth, cost reductions, and deleveraging; current valuation reflects excessive optimism relative to near-term fundamentals. Read the full article on Seeking Alpha
Mise à jour de l'analyse • Apr 22
CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside
Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).Mise à jour de l'analyse • Apr 08
CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside
Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).
Mise à jour de l'analyse • Mar 24
CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership
Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).Mise à jour de l'analyse • Mar 09
CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook
Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.Mise à jour de l'analyse • Feb 22
CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside
Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.Mise à jour de l'analyse • Feb 08
CC: PFAS Class Action Risk Will Limit Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.Article d'analyse • Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth
The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...
Mise à jour de l'analyse • Jan 25
CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook
Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).Mise à jour de l'analyse • Jan 11
CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.Mise à jour de l'analyse • Dec 26
CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks
Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Mise à jour de l'analyse • Dec 12
CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks
Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Mise à jour de l'analyse • Nov 01
CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher
Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.Mise à jour de l'analyse • Oct 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).Mise à jour de l'analyse • Oct 03
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).Mise à jour de l'analyse • Sep 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.Article d'analyse • Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...Article d'analyse • Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...Article d'analyse • Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...Article d'analyse • Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Article d'analyse • May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings
Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...Article d'analyse • Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...Article d'analyse • Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?
The Chemours Company ( NYSE:CC ), might not be a large cap stock, but it saw significant share price movement during...Article d'analyse • Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks
To the annoyance of some shareholders, The Chemours Company ( NYSE:CC ) shares are down a considerable 27% in the last...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$410m |
| Dec 31 2025 | US$9m | US$1m | -US$386m |
| Sep 30 2025 | n/a | n/a | -US$338m |
| Jun 30 2025 | n/a | n/a | -US$430m |
| Mar 31 2025 | n/a | n/a | US$10m |
| Dec 31 2024 | US$6m | US$904k | US$69m |
| Sep 30 2024 | n/a | n/a | US$63m |
| Jun 30 2024 | n/a | n/a | US$106m |
| Mar 31 2024 | n/a | n/a | -US$329m |
| Dec 31 2023 | US$2m | US$532k | -US$253m |
| Sep 30 2023 | n/a | n/a | -US$317m |
| Jun 30 2023 | n/a | n/a | -US$87m |
| Mar 31 2023 | n/a | n/a | US$489m |
| Dec 31 2022 | US$2m | US$463k | US$578m |
Rémunération vs marché: La rémunération totale de Denise M. ($USD 8.60M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 7.08M ).
Rémunération et revenus: La rémunération de Denise M. a augmenté alors que l'entreprise n'est pas rentable.
PDG
Denise M. Dignam (59 yo)
2.3yrs
Titularisation
US$8,595,077
Compensation
Ms. Denise M. Dignam serves as Independent Director at Kulicke and Soffa Industries, Inc. from August 22, 2023. She serves as Chief Executive Officer amd Director at The Chemours Company since March 25, 20...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 2.3yrs | US$8.60m | 0.053% $ 1.9m | |
| Senior VP & CFO | 1.8yrs | US$2.75m | 0.011% $ 399.4k | |
| Senior VP | 3.6yrs | US$1.96m | 0.022% $ 788.1k | |
| President of Advanced Performance Materials | 3.2yrs | US$1.53m | 0.012% $ 411.8k | |
| President of Thermal & Specialized Solutions | 2.8yrs | US$1.67m | 0.0081% $ 289.2k | |
| Controller & Chief Accounting Officer | 1.8yrs | pas de données | 0.0039% $ 137.2k | |
| Vice President of Investor Relations | 2.9yrs | pas de données | pas de données | |
| Chief Human Resources Officer | less than a year | pas de données | pas de données | |
| Interim President of Titanium Technologies & Chemical Solutions Business | 3.2yrs | pas de données | pas de données | |
| Chief Enterprise Enablement Officer | 2.2yrs | pas de données | 0.018% $ 654.5k | |
| President of Titanium Technologies | less than a year | pas de données | 0.0023% $ 82.8k |
2.3yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe de direction de CC est considérée comme expérimentée (ancienneté moyenne 2.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 2.2yrs | US$8.60m | 0.053% $ 1.9m | |
| Independent Chair | 10.8yrs | US$315.00k | 0.015% $ 535.8k | |
| Independent Director | 1.9yrs | US$288.12k | 0% $ 0 | |
| Lead Independent Director | 2.5yrs | US$298.12k | 0.0068% $ 241.3k | |
| Independent Director | 8yrs | US$292.50k | 0.0039% $ 138.6k | |
| Independent Director | 1.1yrs | US$248.75k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$275.00k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$275.00k | 0% $ 0 | |
| Independent Director | 1.1yrs | US$248.75k | 0% $ 0 | |
| Independent Director | 6.9yrs | US$292.50k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$275.00k | 0% $ 0 |
2.2yrs
Durée moyenne de l'emploi
58yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la CC n'est pas considéré comme expérimenté ( 2.2 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/07 05:15 |
| Cours de l'action en fin de journée | 2026/05/07 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
The Chemours Company est couverte par 19 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |